Related Experiment Videos
Implantable cardioverter-defibrillators: expanding indications
1Division of Cardiology and Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA. gnaccarelli@psu.edu
Current Opinion in Cardiology
|June 26, 2004
Summary
This review examines trials on implantable cardioverter-defibrillators (ICDs) for preventing sudden cardiac death. New data and technology will soon change ICD treatment guidelines for high-risk patients.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Technology
Background:
- Sudden cardiac death (SCD) remains a significant cause of mortality.
- Implantable cardioverter-defibrillators (ICDs) are established therapies for secondary prevention of SCD.
- Primary prevention strategies using ICDs are increasingly being investigated.
Purpose of the Study:
- To review recent and ongoing clinical trials evaluating expanded indications for ICDs.
- To assess the role of ICDs in primary prevention of sudden cardiac death.
- To discuss the impact of evolving ICD technology on future treatment guidelines.
Main Methods:
- Systematic review of published and recently completed secondary and primary prevention trials.
- Analysis of data focusing on high-risk patient populations.
- Evaluation of technological advancements in ICDs, including cardiac resynchronization therapy (CRT).
Main Results:
- Recent trials have focused on optimizing ICD use for primary prevention in selected high-risk individuals.
- Emerging data from unpublished trials are expected to further refine patient selection.
- Technological integration, such as ICDs with CRT capabilities, is enhancing therapeutic options.
Conclusions:
- Evidence from completed trials and advancements in ICD technology will likely broaden the scope of ICD indications.
- Future guidelines will incorporate data on primary prevention and novel device features.
- Personalized approaches to ICD implantation will become more prevalent.